Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Hexopyrronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 15/20 | 0.98 |
| ▸ | CHRM2 known ✓ | P08172 | 8/20 | 0.98 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.98 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | HRH1 | P35367 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexopyrronium SCHEMBL5388203 | 1.00 | CHRM3 (0.98) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Hexopyrronium SCHEMBL5388206 | 1.00 | CHRM3 (0.98) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Hexopyrronium SCHEMBL6984703 | 1.00 | CHRM3 (0.98) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Hexopyrronium SCHEMBL5391792 | 1.00 | CHRM3 (0.98) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Hexopyrronium SCHEMBL5388581 | 1.00 | CHRM3 (0.98) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Hexopyrronium SCHEMBL5391795 | 1.00 | CHRM3 (0.98) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Hexopyrronium SCHEMBL5388575 | 1.00 | CHRM3 (0.98) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Hexopyrronium SCHEMBL8445043 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL131054 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL132614 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5008111-A | Pretreating skin with anticholinergic quaternary ammonium salt to suppress perspiration | SCHERING CORPORATION (US) | 1991-04-16 | — | — | US | claimed |
| US-4824676-A | ANTICHOLINERGIC AGENT TO SUPPRESS PERSPIRATION | SCHERING CORPORATION (US) | 1989-04-25 | — | — | US | claimed |
| EP-4088717-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | Chase Pharmaceuticals Corporation (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-4035668-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | Chase Pharmaceuticals Corporation (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20210128528-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2021-05-06 | — | — | US | disclosed |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190091214-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | CHASE PHARMACEUTICALS CORP (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190046506-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2019-02-14 | — | — | US | disclosed |
| WO-2019033068-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | AXOVANT SCIENCES GMBH (CH) | 2019-02-14 | — | — | WO | disclosed |
| US-20190000826-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-01-03 | — | — | US | disclosed |
| EP-0937041-B1 | Use of a pharmaceutically acceptable salt of (3R,2'R)-3-[(Cyclopently-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium for the preparation of a medicament | NOE CHRISTIAN R (DE) | 2003-04-23 | — | — | EP | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| WO-2001008681-A1 | METHODS OF ADMINISTRATION OF GLYCOPYRROLATE COMPOSITIONS | FIRST HORIZON PHARMACEUTICAL CORPORATION (US) | 2001-02-08 | — | — | WO | disclosed |
| EP-0937041-A1 | PURE ENANTIOMER BASIC ARYL-CYCLOALKYL-HYDROXYCARBOXYLIC ACID ESTERS, PROCESS FOR PREPARING THE SAME AND THEIR USE IN MEDICAMENTS | Noe, Christian R. (DE) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998021183-A1 | PURE ENANTIOMER BASIC ARYL-CYCLOALKYL-HYDROXYCARBOXYLIC ACID ESTERS, PROCESS FOR PREPARING THE SAME AND THEIR USE IN MEDICAMENTS | NOE CHRISTIAN R (AT) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | CHRM3 1/4885CHRM2 2/4885CHRM4 3/4885 |
| US-10307409-B2 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | CHRM3, CHRM2, CHRM4 | CHRM3 1/4885CHRM2 2/4885CHRM4 3/4885 |
| US-20190000826-A1 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS | ACHE, CHRNA5, SNCA | CHRM3 32/4885CHRM2 46/4885CHRM4 141/4885 |
| US-20190091214-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | ACHE, BCHE, CHAT | CHRM3 18/4885CHRM2 11/4885CHRM4 72/4885 |
| US-20210128528-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | HTR2A, HTR1A, HTR3B | CHRM3 299/4885CHRM2 251/4885CHRM4 302/4885 |
| US-20190046506-A1 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS | HTR2A, HTR1A, HTR3B | CHRM3 299/4885CHRM2 251/4885CHRM4 302/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CHRM3 4193/4885CHRM2 4525/4885CHRM4 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.